Lifevantage (LFVN) Competitors $9.33 -0.18 (-1.89%) As of 02:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock LFVN vs. CMPX, BCYC, PRTA, RGNX, SLDB, CTMX, FULC, INBX, MNPR, and GLUEShould you be buying Lifevantage stock or one of its competitors? The main competitors of Lifevantage include Compass Therapeutics (CMPX), Bicycle Therapeutics (BCYC), Prothena (PRTA), REGENXBIO (RGNX), Solid Biosciences (SLDB), CytomX Therapeutics (CTMX), Fulcrum Therapeutics (FULC), Inhibrx Biosciences (INBX), Monopar Therapeutics (MNPR), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry. Lifevantage vs. Its Competitors Compass Therapeutics Bicycle Therapeutics Prothena REGENXBIO Solid Biosciences CytomX Therapeutics Fulcrum Therapeutics Inhibrx Biosciences Monopar Therapeutics Monte Rosa Therapeutics Lifevantage (NASDAQ:LFVN) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends. Is LFVN or CMPX more profitable? Lifevantage has a net margin of 4.29% compared to Compass Therapeutics' net margin of 0.00%. Lifevantage's return on equity of 33.75% beat Compass Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lifevantage4.29% 33.75% 15.26% Compass Therapeutics N/A -53.11%-46.14% Which has more volatility & risk, LFVN or CMPX? Lifevantage has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Which has preferable valuation and earnings, LFVN or CMPX? Lifevantage has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifevantage$228.53M0.52$9.81M$0.7412.61Compass Therapeutics$850K588.10-$49.38M-$0.45-8.03 Do analysts prefer LFVN or CMPX? Lifevantage currently has a consensus target price of $30.50, indicating a potential upside of 226.90%. Compass Therapeutics has a consensus target price of $13.10, indicating a potential upside of 262.38%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Compass Therapeutics is more favorable than Lifevantage.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifevantage 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Compass Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.91 Do insiders & institutionals have more ownership in LFVN or CMPX? 35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 22.0% of Lifevantage shares are owned by insiders. Comparatively, 29.8% of Compass Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media refer more to LFVN or CMPX? In the previous week, Lifevantage and Lifevantage both had 5 articles in the media. Compass Therapeutics' average media sentiment score of 0.40 beat Lifevantage's score of -0.11 indicating that Compass Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifevantage 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCompass Therapeutics beats Lifevantage on 9 of the 16 factors compared between the two stocks. Get Lifevantage News Delivered to You Automatically Sign up to receive the latest news and ratings for LFVN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LFVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LFVN vs. The Competition Export to ExcelMetricLifevantageMED/DENTAL IndustryMedical SectorNASDAQ ExchangeMarket Cap$118.91M$15.51B$6.11B$10.53BDividend Yield1.90%1.62%5.51%4.67%P/E Ratio12.6616.8085.7226.89Price / Sales0.522.13580.63183.63Price / Cash8.6213.1226.3031.10Price / Book3.393.0713.236.68Net Income$9.81M$472.95M$3.30B$276.44M7 Day Performance-4.11%-1.01%4.85%3.12%1 Month Performance-22.96%-8.70%8.50%10.19%1 Year Performance-20.12%-10.85%87.78%40.24% Lifevantage Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LFVNLifevantage4.2346 of 5 stars$9.33-1.9%$30.50+226.9%-16.6%$118.91M$228.53M12.66260News CoverageCMPXCompass Therapeutics2.6606 of 5 stars$3.82+2.1%$13.88+263.2%+90.2%$517.18MN/A-8.4920News CoveragePositive NewsAnalyst ForecastBCYCBicycle Therapeutics4.0241 of 5 stars$7.61+2.8%$22.22+192.0%-65.1%$512.87M$35.28M-2.17240Trending NewsGap UpPRTAProthena3.0516 of 5 stars$9.76+3.7%$19.75+102.4%-41.5%$506.54M$135.16M-1.73130Analyst ForecastGap UpRGNXREGENXBIO4.5067 of 5 stars$9.85+2.1%$28.38+188.1%+10.0%$487.46M$83.33M-2.86370News CoverageAnalyst ForecastSLDBSolid Biosciences2.8483 of 5 stars$5.97-2.9%$15.00+151.3%-16.7%$478.89M$8.09M-2.13100Positive NewsCTMXCytomX Therapeutics4.135 of 5 stars$3.23+11.4%$5.42+67.7%+185.2%$478.25M$138.10M5.77170FULCFulcrum Therapeutics0.7988 of 5 stars$8.67-1.9%$9.60+10.7%+148.7%$478.17M$80M-7.11100Positive NewsINBXInhibrx Biosciences1.6036 of 5 stars$32.31-1.1%N/A+136.9%$473.38M$200K-3.05166Positive NewsMNPRMonopar Therapeutics1.7496 of 5 stars$75.90-1.0%$86.22+13.6%+2,058.4%$472.80MN/A-22.7910Analyst ForecastGLUEMonte Rosa Therapeutics2.9452 of 5 stars$7.31-2.4%$15.33+109.8%+50.5%$462.58M$177.99M20.3190Positive News Related Companies and Tools Related Companies Compass Therapeutics Competitors Bicycle Therapeutics Competitors Prothena Competitors REGENXBIO Competitors Solid Biosciences Competitors CytomX Therapeutics Competitors Fulcrum Therapeutics Competitors Inhibrx Biosciences Competitors Monopar Therapeutics Competitors Monte Rosa Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LFVN) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lifevantage Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Lifevantage With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
